Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Abstract

The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment. Concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.